Myasthenia - congenital

Myasthenia - Congenital

Congenital Myasthenia
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Muscle weakness, fatigue
Complications	N/A
Onset	Birth or early childhood
Duration	Lifelong
Types	N/A
Causes	Genetic mutations
Risks	Family history
Diagnosis	Clinical evaluation, genetic testing
Differential diagnosis	N/A
Prevention	N/A
Treatment	Medications, supportive care
Medication	N/A
Prognosis	Variable
Frequency	N/A
Deaths	N/A

Congenital myasthenia refers to a group of neuromuscular disorders characterized by muscle weakness and fatigue due to defects at the neuromuscular junction. Unlike myasthenia gravis, congenital myasthenia is not an autoimmune disorder but is caused by genetic mutations.

Etiology

Congenital myasthenia is caused by mutations in genes that are critical for the function of the neuromuscular junction. These mutations can affect various components such as the acetylcholine receptor, acetylcholinesterase, or other proteins involved in synaptic transmission.

Genetic Mutations

Several genes have been implicated in congenital myasthenia, including:

• CHRNA1: Encodes the alpha subunit of the acetylcholine receptor.
• CHRNB1: Encodes the beta subunit of the acetylcholine receptor.
• CHRND: Encodes the delta subunit of the acetylcholine receptor.
• CHRNE: Encodes the epsilon subunit of the acetylcholine receptor.
• RAPSN: Encodes rapsyn, a protein involved in clustering acetylcholine receptors at the neuromuscular junction.

Clinical Presentation

Symptoms of congenital myasthenia typically present at birth or in early childhood. The severity and specific symptoms can vary depending on the underlying genetic mutation.

Common Symptoms

• Muscle weakness
• Fatigue
• Ptosis (drooping of the eyelids)
• Difficulty swallowing
• Respiratory difficulties

Diagnosis

Diagnosis of congenital myasthenia involves a combination of clinical evaluation, family history, and genetic testing. Electromyography (EMG) and nerve conduction studies may also be used to assess neuromuscular function.

Treatment

Treatment for congenital myasthenia is primarily symptomatic and supportive. Medications that may be used include:

• Acetylcholinesterase inhibitors: Such as pyridostigmine, to enhance neuromuscular transmission.
• 3,4-Diaminopyridine: To increase the release of acetylcholine at the neuromuscular junction.

Supportive care may include physical therapy, respiratory support, and nutritional support.

Prognosis

The prognosis for individuals with congenital myasthenia varies widely depending on the specific genetic mutation and the severity of symptoms. Some individuals may experience significant improvement with treatment, while others may have persistent symptoms.

See Also

• Myasthenia gravis
• Neuromuscular junction
• Genetic disorders

External Links

• Muscular Dystrophy Association - Congenital Myopathies

class="navbox" style="width:100%; background:#F9F9F9; border:2px solid #AAAAAA; padding:5px; font-size:90%;"